The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
521
ALT, FIBROSCAN VCTE, AND FIBROSCAN CAP AS PREDICTIVE MARKERS OF RESMETIROM BIOPSY RESPONSE
Date
May 19, 2024
Explore related products in the following collection:
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form metabolic dysfunction-associated steatohepatitis (MASH) are highly prevalent worldwide. However, current non-invasive diagnostic approaches for MASLD and MASH are suboptimal…